|
|
|
Home >
Health Conditions > Breast Cancer >
Arimidex
Arimidex (anastrozole) - 9/00
Related Topics:
Where to purchase:
Aromatization (in males):
-
Anastrozole (Arimidex) - anabolic-androgenic-steroids.com -
"Anastrozole (Arimidex) is the aromatase inhibitor
of choice" - see
aromatization
-
Middle-Aged Men Can Blame Estrogen, Too - NYTimes.com, 9/11/13 -
"Estrogen, the female sex hormone, turns out to play a
much bigger role in men’s bodies than previously thought, and falling levels
contribute to their expanding waistlines just as they do in women’s"
- [WebMD]
[Abstract]
- Note: Here's the study they cite but something isn't making sense. It says
"the percentage of body fat increased in groups receiving placebo or 1.25 g or
2.5 g of testosterone daily without anastrozole". Anastrozole increases
testosterone and decreases estrogen yet they're saying that body fat increased
without the anastrozole implying that body fat decreased with the anastrozole
(more testosterone, less estrogen). See my
aromatization page. Personally I feel
that this study is doing to way too many things that affect the endocrine system
that makes the outcome suspect. It's disturbing how the media is taking off
with it like it's written in stone. For example, how do they know that
suppressing all those hormones at the beginning then artificially replacing some
didn't also alter others such as insulin, cortisol, the thyroid hormones, etc.
which might affect fat? Blaming it on estrogen seems like a long shot.
- Gonadal
Steroids and Body Composition, Strength, and Sexual Function in Men
- NEJM, 9/10/12 - "We provided 198 healthy men
20 to 50 years of age with goserelin acetate (to suppress endogenous
testosterone and estradiol) and randomly assigned them to receive a
placebo gel or 1.25 g, 2.5 g, 5 g, or 10 g of testosterone gel daily for
16 weeks. Another 202 healthy men received goserelin acetate, placebo
gel or testosterone gel, and anastrozole (to suppress the conversion of
testosterone to estradiol) ... The percentage of body fat increased in
groups receiving placebo or 1.25 g or 2.5 g of testosterone daily
without anastrozole (mean testosterone level, 44+/-13 ng per deciliter,
191+/-78 ng per deciliter, and 337+/-173 ng per deciliter,
respectively). Lean mass and thigh-muscle area decreased in men
receiving placebo and in those receiving 1.25 g of testosterone daily
without anastrozole ... The amount of testosterone required to maintain
lean mass, fat mass, strength, and sexual function varied widely in men.
Androgen deficiency accounted for decreases in lean mass, muscle size,
and strength; estrogen deficiency primarily accounted for increases in
body fat; and both contributed to the decline in sexual function"
- Letrozole
suppresses plasma estradiol and estrone sulphate more completely
than anastrozole in postmenopausal women with breast cancer - J
Clin Oncol. 2008 Apr 1;26(10):1671-6 -
"Letrozole reduces plasma E2 and E1S levels to a significantly
greater extent than anastrozole"
- Influence
of letrozole and anastrozole on total body aromatization and plasma
estrogen levels in postmenopausal breast cancer patients evaluated
in a randomized, cross-over study - J Clin Oncol. 2002 Feb
1;20(3):751-7 -
"estrone (E(1)), estradiol (E(2)), and
estrone sulfate (E(1)S) ... Treatment with anastrozole suppressed
plasma levels of E(1), E(2), and E(1)S by a mean of 81.0%, 84.9%,
and 93.5%, respectively, whereas treatment with letrozole caused a
corresponding decrease of 84.3%, 87.8% and 98.0%, respectively. The
suppression of E(1) and E(1)S was found to be significantly better
during treatment with letrozole compared with anastrozole"
-
Reducing the side effects of treatment for prostate cancer - Science
Daily, 8/24/12 - "tamoxifen reduced the risk of both
gynecomastia and breast pain at 3, 6, 9, and 12 months of treatment compared
to men who received no treatment. Overall, treatment with tamoxifen was more
successful in reducing breast symptoms than treatment with an aromatase
inhibitor (anastrazole) or radiotherapy" - Note: They left out
Femara (letrozole).
-
Aromatase Inhibition Offers Little Benefit, Possible Harm to Men With Lo...
- Medscape, 12/22/09 - "The inescapable conclusion from
these data is that the 50% increase in testosterone levels was trumped by the
much more modest 20% reduction in estradiol levels, leading to negative skeletal
effects of anastrozole therapy in aging men" - Note: I'm not sure
that thought this though thoroughly. Mortally in men is best when estrogen
is around 25pg/mL. I suspect that most have higher estrogen than that.
See:
-
High, Low Estradiol Levels and Mortality in Men With Systolic HF -
Medscape, 5/19/09 - "Both low and high serum levels
of estradiol, compared with mid-range levels, are significantly and
independently associated with increased all-cause mortality in men with
chronic systolic heart failure"
Serum Estradiol Concentration Quintiles as Predictors of All-Cause Mortality
in Men (With Quintile 3 as the Reference Group)
| Parameter |
Quintile 1 |
Quintile 2 |
Quintile 3 |
Quintile 4 |
Quintile 5 |
| Estradiol concentration (pg/mL) |
<12.903 |
12.90–21.79 |
21.80–30.11 |
30.12–37.39 |
>37.40 |
| 3-y survival* (%) |
44.6 |
65.8 |
82.4 |
79.0 |
63.6 |
| Quintile as mortality predictor,* HR (95% CI) vs quintile 3 |
4.17 (2.33–7.45) |
2.15 (1.16–3.99) |
-- |
1.22 (0.64–2.31) |
2.33 (1.30–4.18) |
HR= hazard ratio
-
Ibandronate Can Prevent Anastrozole-Induced Bone Loss - Medscape, 6/6/07
-
Drug
Combination May Slow Male Breast Cancer Growth - Science Daily, 7/7/06
-
Testosterone Deficiency & Depression, Does DHEA Raise the Levels of
Bioavailable Testosterone in Men? - Life Extension Magazine, 8/02 -
"Some men on testosterone drug replacement therapy
develop dangerously high estrogen levels. Estrogen can be suppressed by
taking an aromatase-inhibiting drug like Arimidex (0.5 mg twice a week) or
using a supplement like Super Mira Forte (six capsules daily)"
-
Male Hormone
Modulation Therapy - Life Extension Magazine -
"If all of the above fail to increase free
testosterone and lower excess estradiol, then ask your doctor to prescribe
the potent aromatase inhibiting drug Arimidex (anastrozole) in the very low
dose of one-half (0.5 mg) mg, twice a week"
-
Estrogen suppression in males: metabolic effects - J Clin Endocrinol
Metab. 2001 Apr;86(4):1836-8 -
"First, a dose-response study of 12 males (mean age,
16.1 +/- 0.3 yr) was conducted, and blood withdrawn at baseline and after 10
days of oral Arimidex given as two different doses (either 0.5 or 1 mg) in
random order with a 14-day washout in between. A sensitive estradiol (E2)
assay showed an approximately 50% decrease in E2 concentrations with either
of the two doses ... There was a 58% increase in serum T"
CME:
News & Research:
-
Joint Supplements for
Aromatase Inhibitor Adverse Effects - Medscape, 11/18/11 -
"Aromatase inhibitors are widely used in the
treatment of breast cancer but are associated with significant
musculoskeletal adverse effects, including joint pain and stiffness ... We
know that these symptoms are unresponsive to conventional pain medication
and often lead to low adherence to aromatase inhibitor therapy ... The
cohort consisted of postmenopausal breast cancer patents with stage I to III
disease who had been on aromatase therapy for at least 3 months, who
reported a pain rating of 4 or higher on a 10-point visual analog scale, and
whose pain worsened after initiating treatment with aromatase inhibitors if
they had preexisting osteoarthritis ... Participants took 1500 mg/day of
glucosamine and 1200 mg/day of chondroitin, and were evaluated every 6 weeks
at the clinic ... There was a drop in pain and stiffness in the hips and
knees at 12 and 24 weeks, as well as improvement in function. "This affected
about 50% of the women," she explained. "We saw a very similar pattern
looking at the hands and the wrist. We saw similar results with the Brief
Pain/Stiffness Inventory — with about 35% to 50% of women."" - See
glucosamine products at Amazon.com
and
chondroitin sulfate at Amazon.com.
-
Toxicity of aromatase inhibitors may explain lack of overall survival
improvement - Science Daily, 8/22/11 - "compared
to tamoxifen, longer use of AIs was
associated with increased heart disease and bone fractures, but lower rates
of blood clots and cancer of the womb. There were no differences in the risk
of stroke or other types of cancer. Furthermore, use of AIs for 2-3 years
after initial treatment with tamoxifen was associated with a lower risk of
death unrelated to breast cancer compared to the use of either AIs or
tamoxifen alone. The authors therefore concluded that the toxicity of AIs
when used for longer periods of treatment may explain the lack of overall
survival benefit while still having a positive effect on breast cancer
recurrence"
-
Vitamin D relieves joint, muscle pain for breast cancer patients -
Science Daily, 7/26/11 - "Rastelli's group recruited
60 patients who reported pain and discomfort associated with anastrozole,
one of three FDA-approved aromatase inhibitors. The patients they studied
also had low vitamin D levels. Half the group was randomly assigned to
receive the recommended daily dose of vitamin D (400 international units)
plus a 50,000-unit vitamin D capsule once a week. The other half received
the daily dose of 400 units of vitamin D plus a weekly placebo. All subjects
received 1,000 milligrams of calcium daily throughout the study ... patients
receiving high-dose vitamin D every week reported significantly less
musculoskeletal pain and also were less likely to experience pain that
interfered with daily living" - See
vitamin D at Amazon.com.
-
Anastrozole Accelerates Bone Loss - Medscape, 3/18/08 -
"Anastrozole-treated women experienced a decrease in
median BMD from baseline to 5 years in the lumbar spine (-6.08%) and total
hip (-7.24). Tamoxifen-treated women had an increase in median BMD over the
5-year period in lumbar spine (+2.77%) and total hip (+0.74%)"
-
Anastrozole's Superiority in Preventing Recurrence Confirmed In 100-Month
ATAC Follow-Up - oncologystat.com, 12/20/07
-
Vitamin D Supplementation Reduces Fatigue and Muscle Pain in Women With
Early-Stage Breast Cancer - Doctor's Guide, 12/17/07 -
"Treatment of low levels of vitamin D in women with
early stage breast cancer appears to reduce fatigue and muscle pain
associated with aromatase inhibitor therapy" - See
vitamin D at Amazon.com.
-
Breast Cancer: Arimedex vs. Tamoxifen - WebMD, 12/14/07
-
Extended Adjuvant
Aromatase Inhibitor Therapy Beneficial in Breast Cancer - Medscape,
12/11/07 - "Women with breast cancer who complete 5
years of tamoxifen therapy derive significant benefit from an additional 3
years of treatment with the aromatase inhibitor anastrozole"
-
Pain Makes Some End Breast Cancer Drug - WebMD, 9/6/07 -
"23% of the women in the new study given one of two
aromatase inhibitors -- Aromasin or Femara -- stopped taking their drugs due
to side effects, which also included hot flashes and nausea ... Forty-two
percent of the women reported serious bone and joint problems, such as
severe pain or difficulty opening a jar, and were referred for evaluation by
a rheumatologist"
-
Anastrozole Less Likely to Cause Venous Thromboembolism Than Tamoxifen -
Doctor's Guide, 12/19/06
-
Drug Switch Ups Breast Cancer Survival - WebMD, 11/17/06
-
Women With Early Breast Cancer are More Likely to Remain Cancer Free by
Changing Treatment From Tamoxifen to Anastrozole - Doctor's Guide,
11/17/06
-
Aromatase Inhibitors Declared Superior to Tamoxifen in the Adjuvant
Treatment of Early Breast Cancer - Doctor's Guide, 8/1/06
- Five Years on
Anastrozole Can Promote Progression to Osteoporosis - Medscape, 6/12/06
- "Women taking anastrozole also had about a 40%
increased risk of fractures while on the study ... At 5 years, women taking
anastrozole lost 6.1% of BMD at the hip and 7.2% at the spine ... women with
a normal BMD at baseline did not develop osteoporosis"
-
Patients Who Switch From Tamoxifen to Anastrozole Have Longer Survival and
Time to Progression - Doctor's Guide, 6/4/06
-
Bone Loss Associated with Aromatase Inhibitor Therapy for Breast Cancer
Confirmed - Doctor's Guide, 6/4/06 -
"Aromatase inhibitor use was associated with a
relative risk (RR) ratio of 1.3"
-
Neoadjuvant Aromatase Inhibitors May Be as Effective as Chemotherapy in
Locally Advanced Breast Cancer - Doctor's Guide, 3/27/06
-
Five-Year Data from Austrian Trial Shows Significant Benefit in Switching
From Tamoxifen to Anastrozole - Doctor's Guide, 12/14/05
-
No Differences in Time to Response for Fulvestrant and Anastrozole in
Advanced Breast Cancer Patients - Doctor's Guide, 12/13/05
-
Survival Advantage of Anastrozole over Tamoxifen Seen in Meta Analysis -
Doctor's Guide, 12/12/05
-
Fewer Gynecological Problems Seen in Women on Anastrozole in ATAC Study
- Doctor's Guide, 12/12/05
-
Long-term Consequences of the Aromatase Inhibitors - Medscape, 11/16/05
- "The "short-term toxicities," such as vasomotor
symptoms, venothromboemboli, and gynecologic complications, favor the use of
AIs. However, long-term bone loss, altered lipid profiles, and possible
compromise in sexual functioning appear to be adversely affected by the AIs"
-
Anastrozole Has Better Risk:Benefit Profile than Tamoxifen for Breast Cancer
Patients - Doctor's Guide, 11/2/05
-
Aromatase Inhibitors Have Different Cardiovascular Safety Profiles -
Doctor's Guide, 11/2/05
-
Arimidex (Anastrozole) Gains Full FDA Approval for Adjuvant Treatment of
Hormone Receptor-Positive Early Breast Cancer in Postmenopausal Women -
Doctor's Guide, 9/20/05
-
Arimidex (Anastrozole) Granted New Indication Enabling Wider Access for
Postmenopausal Women With Breast Cancer - Doctor's Guide, 6/28/05
-
Long-Term Use of Anastrozole Shows Benefits in Women Who Have Completed
Tamoxifen Therapy - Doctor's Guide, 5/213/05
-
Anastrozole for 6 Months Aids Breast Conservation in Older Women -
Doctor's Guide, 3/4/05
-
5 Years of Adjuvant Treatment With Anastrozole (Arimidex) Shows Better
Results Than Tamoxifen in Breast Cancer - Doctor's Guide, 2/2/05
-
Women With Hormone-Sensitive Early Breast Cancer Benefit from Switch to
Anastrozole After 2 Years Adjuvant Tamoxifen - Doctor's Guide, 1/31/05
- Trials Support
Replacing Tamoxifen With Anastrozole at Two Years - Medscape, 12/9/04
-
Anastrozole Continues to Show Benefits Over Tamoxifen - Doctor's Guide,
12/9/04
-
Arimidex (Anastrozole) Appears Superior to Tamoxifen in Reducing Breast
Cancer Recurrence - Doctor's Guide, 12/9/04
- Arimidex Beats
Gold Standard Tamoxifen - WebMD, 12/8/04
-
Emerging Successes of Aromatase Inhibitor Switching Trials Likely to
Influence Practice Patterns, Future Trials - Doctor's Guide, 7/29/04
-
Benefits of Aromatase Inhibitors Should Outweigh Physicians' Concerns About
Long-Term Toxicity Issues - Doctor's Guide, 7/29/04
-
Aromatase Inhibitors Still Superior Over Tamoxifen, but Questions Remain
About Estrogen Receptor Factors - Doctor's Guide, 7/27/04
-
New Aromatase Inhibitors Similarly Effective Despite Differences in
Oestrogen Suppression - Doctor's Guide, 6/30/04
-
Neoadjuvant Therapy With Anastrozole Doubles Rate of Surgical Downstaging
from Mammography to Lumpectomy - Doctor's Guide, 4/29/04
-
Anastrozole Might Have Superior Tolerability Profile Compared to Tamoxifen
- Doctor's Guide, 4/29/04
-
Study Suggests Anastrozole Fracture Risk Stabilizes Over Time - Doctor's
Guide, 4/29/04
-
Fulvestrant Appears Comparable to Anastrozole Therapies for Treatment of
Hormone Receptor-Positive Metastatic Breast Cancer - Doctor's Guide,
4/29/04
-
Anastrozole Potentially More Effective Than Tamoxifen Against
Hormone-Sensitive Breast Cancer - Doctor's Guide, 3/23/04
-
Anastrozole Protective Against Endometrial Cancer - Doctor's Guide,
3/22/04
-
Anastrozole vs. Tamoxifen: Risk of Bone Loss Outweighed By Tolerability in
Early Breast-Cancer Therapy - Doctor's Guide, 3/22/04
-
Goserelin and Anastrozole as Second-Line Endocrine Therapy in Premenopausal
Breast Cancer Patients Appears Safe, Effective - Doctor's Guide, 3/9/04
-
Anastrozole Shows Promise for Breast Cancer Chemoprevention - Doctor's
Guide, 2/17/04
-
Molecular Marker Finds Newer Hormonal Therapy Slows Tumor Growth More -
Doctor's Guide, 12/5/03
-
Pre-Surgical Hormonal Therapy With Aromatase Inhibitor May Shrink More
Breast Tumors - Doctor's Guide, 12/4/03
- Arimidex Helps
Shrink Breast Cancer Tumors - WebMD, 12/4/03
- Anastrozole Replaces
Adjuvant Tamoxifen - Medscape, 12/4/03
- Neoadjuvant
Anastrozole Reduces Need for Mastectomy - Medscape, 12/3/03
- Drug Switch
Staves Off Breast Cancer - WebMD, 12/3/03
-
Benefits of Anastrozole Outweigh Risk of Bone Fractures Compared with
Tamoxifen - Doctor's Guide, 9/29/03
-
Worries Lessen Over New Breast Cancer Drug - HealthDay, 9/26/03
- Fracture Risk With
Anastrozole Levels off in Postmenopausal Women - Medscape, 9/23/03
-
Fracture Risk with Anastrozole (Arimidex) Stops Increasing After Two Years
of Treatment - Doctor's Guide, 8/6/03
-
Fulvestrant (Faslodex) Demonstrates Non-inferiority to Anastrozole in
Advanced Hormone-Sensitive Breast Cancer - Doctor's Guide, 8/5/03
-
Anastrozole (Arimidex) Shows Efficacy and Safety in Receptor-positive Breast
Cancer - Doctor's Guide, 4/14/03
-
Anastrozole Extends Overall Survival Compared to Tamoxifen in Postmenopausal
Breast Cancer - Doctor's Guide, 2/6/03
-
Anastrozole Effective for Advanced Ovarian, Peritoneal and Fallopian Tube
Carcinomas - Doctor's Guide, 2/4/03
- Anastrozole Superior
to Tamoxifen as Adjuvant Treatment in Early Breast Cancer - Medscape,
12/13/02
-
Anastrozole-Tamoxifen Sequence Best for Advanced Breast Cancer -
Doctor's Guide, 12/13/02
-
Arimidex (Anastrozole) Continues to Show Benefits Over Tamoxifen in
Early-stage Breast Cancer - Doctor's Guide, 12/12/02
- Arimidex Better
Than Tamoxifen Long Term - WebMD, 12/11/02
- New Treatment Options
in Advanced Breast Cancer - Medscape, 12/11/02 -
"A double-blind crossover trial showed that
anastrozole (ARI) should be given as first-line adjuvant therapy with
tamoxifen (TAM) used after first progression for women with advanced
breast cancer"
-
Anastrozole Superior to Tamoxifen in Early Post-menopausal Breast Cancer
- Doctor's Guide, 10/21/02
-
Anastrozole is Better Than Tamoxifen for Treatment of Postmenopausal Women
with Advanced Breast Cancer - Doctor's Guide, 10/21/02
-
Anastrozole Could Be Associated with Fewer Endometrial Abnormalities than
Tamoxifen in Early Breast Cancer - Doctor's Guide, 10/19/02
-
Astrazeneca Granted U.S. Approval For Arimidex (Anastrozole) In Early Breast
Cancer - Doctor's Guide, 9/6/02
- Fulvestrant as
Effective as Anastrozole in Breast Cancer - Medscape, 8/19/02
-
Anastrozole An Option For Postmenopausal Hormone-Sensitive Early Breast
Cancer - Doctor's Guide, 6/21/02
- Breast Cancer
Drug [Arimidex] Continues to Shine - WebMD, 6/20/02
- Letrozole Produces Better
Response than Anastrozole in Advanced Breast Cancer - Doctor's Guide,
5/22/02
- Head-To-Head Worldwide
Study Of The Two Leading Aromatase Inhibitors Shows More Women Respond To
Femara (Letrozole) Than Arimidex (Anastrozole) In Advanced Breast Cancer
- Doctor's Guide, 5/21/02
-
Study Reports on Endometrial Changes Comparing Tamoxifen With Arimidex
(Anastrazole) in Postmenopausal Women Treated for Early Breast Cancer -
Doctor's Guide, 5/21/02
- New Breast Cancer
Drug [Arimidex] Tops Tamoxifen - WebMD, 3/27/02
-
Arimidex (Anastrozole) Agent of Choice for Future Chemoprevention/Risk
Reduction Studies in Breast Cancer - Doctor's Guide, 2/15/02
- Femara (Letrozole) More
Effective Than Arimidex (Anastrozole) at Inhibiting Estrogen in Advanced
Breast Cancer - Doctor's Guide, 1/31/02
- FDA Grants Fast-Track
Status to Arimidex (Anastrozole) for Early Breast Cancer - Doctor's
Guide, 1/14/02
- Anastrozole (Arimidex)
Outperforms Tamoxifen and Combination in Adjuvant Breast Cancer -
Doctor's Guide, 12/11/01
- Improved Clinical Outcomes
With Anastrozole In Advanced Breast Cancer With Visceral Metastases -
Doctor's Guide, 10/24/01
- Single Monthly Injections
with Faslodex (Fulvestrant) as Effective as Anastrazole in Post-Menopausal
Advanced Breast Cancer - Doctor's Guide, 11/1/01
- Arimidex (Anastrozole)
Shown to be Gold Standard for Advanced Breast Cancer - Doctor's Guide,
10/19/01
- Arimidex (Anastrozole)
Followed By Tamoxifen Highly Effective For Advanced Breast Cancer -
Doctor's Guide, 9/19/01
- Anti-Aromatase Agents
Cost-Effective For Women With Metastatic Breast Cancer - Doctor's Guide,
5/15/01
- Arimidex Reinforced As A
First-Line Choice For Patients With Aggressive Metastatic Breast Cancer
- Doctor's Guide, 5/12/01
- Better Survival With
Arimidex (Anastrozole) Than Tamoxifen In Postmenopausal Women With Advanced
Breast Cancer - Doctor's Guide, 12/11/00
- First-Line Anastrozole
Effective Against Advanced Breast Cancer After Tamoxifen - Doctor's
Guide, 12/8/00
- Faslodext (ICI182,780) At
Least As Effective As Arimidex (Anastrozole) In Advanced Breast Cancer -
Doctor's Guide, 12/7/00
- Arimidex (Anastrozole)
First-Line Therapy Highly Effective For Advanced Breast Cancer -
Doctor's Guide, 9/28/00
- FDA Approves Arimidex
(Anastrozole) For Hormone Receptive Advanced Breast Cancer - Doctor's
Guide, 9/5/00
- Neoadjuvant Therapy With
Hormones May Avoid Some Mastectomies in Post-Menopausal Women - Doctor's
Guide, 6/6/00
- Anastrozole May Replace
Tamoxifen In Postmenopausal Breast Cancer - Doctor's Guide, 2/1/00
- Arimidex More Effective
Than Nolvadex For Advanced Breast Cancer - Doctor's Guide, 12/10/99
- Anastrozole As Effective
As Tamoxifen For Advanced Breast Cancer In Postmenopausal Women -
Doctor's Guide, 9/15/99
- Zeneca Receives FDA
Clearance for Arimidex to Treat Breast Cancer - Doctor's Guide, 1/31/96
Abstracts:
Related Searches:
70521
|
|
